| Print
Amicus Therapeutics (FOLD)
Common SharesNot yet a customer?
Low cost dealing from £1.50Choose from our range of SIPP, ISA and Dealing accounts
Find out moreThis share can be held in a Dealing accountStocks and shares ISALifetime ISAJISASIPP
Company profile
Amicus Therapeutics Inc is a patient-dedicated biotechnology company focused on discovering, developing and delivering novel high-quality medicines for people living with rare diseases. With extraordinary patient focus, the company is committed to advancing and expanding a pipeline of cutting-edge medicines for rare diseases. It has a portfolio of product opportunities, including oral precision medicine for people living with Fabry disease who have amenable genetic variants;a clinical-stage, treatment paradigm for Pompe disease, and a rare disease gene therapy portfolio. The company has one segment focused on the discovery, development, and commercialization of therapies to treat a range of devastating rare and orphan diseases.
Address
1 Cedar Brook Drive
Cranbury
NJ
USA
08512
Telephone
+1 609 662-2000
Forecast key dates
| Name | Key Date |
|---|---|
| Amicus Therapeutics Inc Second Quarter Earnings Conference Call for 2026 | 2026-07-31T08:30:00 |
| Amicus Therapeutics Inc Second Quarter Earnings Results for 2026 | 2026-07-31T00:00:00 |
| Amicus Therapeutics Inc Annual General Meeting for 2026 | 2026-06-05T09:00:00 |
| Amicus Therapeutics Inc First Quarter Earnings Conference Call for 2026 | 2026-05-01T08:30:00 |
| Amicus Therapeutics Inc First Quarter Earnings Results for 2026 | 2026-05-01T00:00:00 |
| Amicus Therapeutics Inc Fourth Quarter Earnings Conference Call for 2025 | 2026-02-19T08:30:00 |
| Amicus Therapeutics Inc Fourth Quarter Earnings Results for 2025 | 2026-02-19T00:00:00 |
| Amicus Therapeutics Inc Annual Report for 2025 | 2026-02-19T00:00:00 |
| Amicus Therapeutics Inc Third Quarter Earnings Conference Call for 2025 | 2025-11-06T08:30:00 |
| Amicus Therapeutics Inc Third Quarter Earnings Results for 2025 | 2025-11-06T00:00:00 |
Previous key dates
AJ Bell Management Limited (company number 03948391), AJ Bell Securities Limited (company number 02723420) and AJ Bell Asset Management Limited (company number 09742568) are authorised and regulated by the Financial Conduct Authority. All companies are registered in England and Wales at 4 Exchange Quay, Salford Quays, Manchester M5 3EE. See website for full details. AJ Bell procures the provision of the Morningstar Licensed Tools on an “as is” basis and does not guarantee the performance of or accept liability for the Licensed Tools. To the maximum extent permitted by law, AJ Bell excludes liability for the Licensed Tools, including liability for any failure, interruption, delay or defect in the performance of any Licensed Tool, unless it arises as a direct result of the negligence of AJ Bell.
© Copyright 2025 AJ Bell. All rights reserved.